WallStreetZenWallStreetZen

NYSEMKT: MTNB
Matinas Biopharma Holdings Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Matinas Biopharma Holdings earnings were -$11.2M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest MTNB earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$1.9M, up 0.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MTNB reported annual earnings of -$11.0M, with -54.8% growth.

MTNB earnings history

Current Revenue
$0.0
Current Earnings
-$11.2M
Current Profit Margin
0%

MTNB Return on Equity

Current Company
-204.3%
Current Industry
-142%
Current Market
13.5%
MTNB's Return on Equity (-204.3%)... subscribe to Premium to read more.
High Return on Equity Performance

MTNB Return on Assets

Current Company
-131.3%
Current Industry
-13.7%
MTNB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MTNB announces earnings.

MTNB Return on Capital Employed

Current Company
-283.08%
Current Industry
-9.5%
MTNB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

MTNB vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MTNB-$10.21M-$11.23MN/A-$1.99
INM-$7.91M-$8.51MN/A-$2.11
RNAZ-$39.81M-$43.70MN/A-$50.33
CLGN-$12.25M-$13.13MN/A-$1.03
PULM-$4.53M-$4.53MN/A-$1.23
View Top Biotech Stocks

Matinas Biopharma Holdings Earnings Reports & History FAQ

What were Matinas Biopharma Holdings's earnings last quarter?

Matinas Biopharma Holdings (NYSEMKT: MTNB) reported Q1 2026 earnings per share (EPS) of -$0.30, up 9.09% year over year. Total MTNB earnings for the quarter were -$1.92 million. In the same quarter last year, Matinas Biopharma Holdings's earnings per share (EPS) was -$0.33.

If you're new to stock investing, here's how to buy Matinas Biopharma Holdings stock.

Is Matinas Biopharma Holdings profitable or losing money?

As of the last Matinas Biopharma Holdings earnings report, Matinas Biopharma Holdings is currently losing money. Matinas Biopharma Holdings's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$10.61 million, a 47.17% decrease year over year.

What was MTNB's earnings growth in the past year?

As of Matinas Biopharma Holdings's earnings date in Q2 2026, Matinas Biopharma Holdings's earnings has grown year over year. MTNB earnings in the past year totalled -$11.23 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.